These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3467512)

  • 1. Augmentation of hydroxyurea cytotoxicity by sintamil in human chronic myeloid leukemia cells.
    Pradhan SG; Chitnis MP; Basrur VS; Satyamoorthy K; Advani SH
    Tumori; 1986 Oct; 72(5):507-10. PubMed ID: 3467512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiation of hydroxyurea cytotoxicity in human chronic myeloid leukemia cells by iron-chelating agent.
    Satyamoorthy K; Chitnis MP; Basrur VS; Advani SH
    Leuk Res; 1986; 10(11):1327-30. PubMed ID: 3099095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of sensitivity to mitoxantrone in human chronic myeloid leukemia cells by the antidepressant sintamil.
    Chitnis MP; Satyamoorthy K; Pradhan SG; Advani SH
    Oncology; 1988; 45(4):292-6. PubMed ID: 3164462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea.
    Hehlmann R; Berger U; Pfirrmann M; Hochhaus A; Metzgeroth G; Maywald O; Hasford J; Reiter A; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Griesshammer M; Nerl C; Kuse R; Tobler A; Eimermacher H; Tichelli A; Aul C; Wilhelm M; Fischer JT; Perker M; Scheid C; Schenk M; Weiss J; Meier CR; Kremers S; Labedzki L; Schmeiser T; Lohrmann HP; Heimpel H;
    Leukemia; 2003 Aug; 17(8):1529-37. PubMed ID: 12886239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro cytotoxicity of caracemide alone and in combination with hydroxyurea or iron-chelating agents in human chronic myeloid leukemia cells and murine tumors.
    Satyamoorthy K; Chitnis MP; Advani SH
    Neoplasma; 1988; 35(1):27-35. PubMed ID: 3162554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxyurea potentiation of the antineoplastic activity of cyclophosphamide and 4'-(9-acridinylamino)methanesulfon-M-anisidide (AMSA) in the brown Norway rat myelocytic leukemia model.
    Vaughan WP; Holm C; Cordel K
    Cancer Chemother Pharmacol; 1989; 23(1):26-30. PubMed ID: 2909287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of thymidine and hydroxyurea on the metabolism and cytotoxicity of 1-B-D arabinofuranosylcytosine in highly resistant human leukemia cells.
    Bhalla K; Swerdlow P; Grant S
    Blood; 1991 Dec; 78(11):2937-44. PubMed ID: 1954383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of mitoxantrone on human chronic myeloid leukemia cells in vitro, combined with hyperthermia.
    Juvekar AS; Chitnis MP; Adwankar MK; Advani SH
    Neoplasma; 1986; 33(4):477-82. PubMed ID: 3463880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1,10-phenanthroline potentiates cytotoxicity of hydroxyurea in human chronic myeloid leukemia cells.
    Kamath NS; Satyamoorthy K; Chitnis MP; Advani SH
    Oncology; 1989; 46(3):193-7. PubMed ID: 2717131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyurea and 6-mercaptopurine in the treatment of chronic granulocytic leukemia.
    Lazzarino M; Morra E; Brusamolino E; Inverardi D; Castelli G; Merante S; Bernasconi C
    Am J Clin Oncol; 1986 Feb; 9(1):45-9. PubMed ID: 3513537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxyurea enhances 3'-azido-3'-deoxythymidine (AZT) cytotoxicity in human chronic myeloid leukemia models.
    Tosi P; Visani G; Ottaviani E; Tura S; Darnowski JW
    Eur J Haematol; 1994 May; 52(5):291-5. PubMed ID: 8020629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha.
    Hehlmann R; Anger B; Messerer D; Zankovich R; Bergmann L; Kolb HJ; Meyer P; Essers U; Queisser U; Vaupel H
    Blut; 1988 Feb; 56(2):87-91. PubMed ID: 3277680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitoxantrone & adriamycin cytotoxicity enhanced by reserpine in human chronic myeloid leukaemia cells.
    Chitnis MP; Kamath NS; Advani SH
    Indian J Med Res; 1989 Jun; 90():197-202. PubMed ID: 2767744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro modulation of adriamycin and mitoxantrone cytotoxicity by hyperthermia and diazepam, in human chronic myeloid leukemia cells.
    Juvekar AS; Chitnis MP; Advani SH
    Neoplasma; 1987; 34(2):199-204. PubMed ID: 3474531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1
    Schneeweiss-Gleixner M; Byrgazov K; Stefanzl G; Berger D; Eisenwort G; Lucini CB; Herndlhofer S; Preuner S; Obrova K; Pusic P; Witzeneder N; Greiner G; Hoermann G; Sperr WR; Lion T; Deininger M; Valent P; Gleixner KV
    EBioMedicine; 2019 Dec; 50():111-121. PubMed ID: 31761618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.
    Silver RT; Woolf SH; Hehlmann R; Appelbaum FR; Anderson J; Bennett C; Goldman JM; Guilhot F; Kantarjian HM; Lichtin AE; Talpaz M; Tura S
    Blood; 1999 Sep; 94(5):1517-36. PubMed ID: 10477676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-alpha and hydroxyurea in early chronic myeloid leukemia: a comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-alpha.
    Hasford J; Baccarani M; Hehlmann R; Anseri H; Tura S; Zuffa E
    Blood; 1996 Jun; 87(12):5384-91. PubMed ID: 8652857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with interferon alfa-2b and hydroxyurea during the accelerated phase of chronic myelogenous leukemia.
    Bourantas KL; Syrou M; Tsiara S; Danella M; Konstantinides P
    Acta Haematol; 1996; 95(2):117-21. PubMed ID: 8638440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell kill kinetics with hydroxyurea.
    Yataganas X; Strife A; Perez A; Clarkson B
    Med Pediatr Oncol; 1976; 2(1):39-54. PubMed ID: 1064742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
    Zhang GS; Liu DS; Dai CW; Li RJ
    Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.